NP 02 - CNBX Pharmaceuticals
Alternative Names: NP-02 CNBX PharmaceuticalsLatest Information Update: 06 May 2024
Price :
$50 *
At a glance
- Originator CNBX Pharmaceuticals
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Mental disorders
Most Recent Events
- 25 Apr 2024 Early research in Mental disorders in USA (unspecified route) before April 2024 (CNBX Pharmaceuticals pipeline, April 2024)
- 25 Apr 2024 CNBX Pharmaceuticals plans a preclinical study for Mental disorder (CNBX Pharmaceuticals pipeline, April 2024)